CORT Stock Analysis: Buy, Sell, or Hold?
CORT - Corcept Therapeutics Inc.
$47.01
0.39 (0.84%)
▲
5d:
+0.94%
30d:
+23.32%
90d:
+2.53%
HOLD
MODERATE Confidence
Analysis Updated: Apr 28, 2026 12:00 AM ET
Earnings: May 04, 2026
4d
Smart Money Distribution
CORT is up 3.4% this week, but smart money is buying puts. Top strike: $35 2026-05-15 with 5,122 OI. Put ratio: 82% View Scanner →
Strength: 4.9/10
Get Alerted When CORT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: CORT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: CORT shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$78.28
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$48.61
3.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CORT is currently trading at $47.01, which is considered extended relative to its 30-day fair value range of $35.81 to $44.76. From a valuation perspective, the stock is trading at a discount (Forward PE: 29.0) compared to its historical average (45.0). Remarkably, the market is currently pricing in an annual earnings decline of 13.6% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CORT is in a strong downtrend. The price is approaching resistance at $47.09. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CORT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $67.40 (+44.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, CORT is in a strong downtrend. The price is approaching resistance at $47.09. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: CORT has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $67.40 (+44.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$35.81 -
$44.76
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding CORT? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range (+5.0% above its trading range)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 44.6% below Wall St target ($67.40)
Trading Range Analysis
30-Day Trading Range
$35.81 -
$44.76
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$43.20
Resistance Level
$47.09
Current Trend
Strong Downtrend
Technical data as of
Apr 28, 2026
Fundamental Context
Forward P/E (Next Year Est.)
28.99
Wall Street Target
$67.40
(+44.6%)
Revenue Growth (YoY)
11.1%
Earnings Growth (YoY)
-21.6%
Profit Margin
13.1%
Valuation Discount vs History
-13.6% cheaper
PE vs Historical
29.0 vs 45.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-13.6%
(market-implied from PE analysis)
1-Year Target
$41.96
(-10%)
2-Year Target
$37.76
(-19%)
3-Year Target
$33.99
(-27%)
3-Yr Target (if PE normalizes)
(PE: 29→45)
$52.75
(+13%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 29.0, Growth: 296.1%)
$157.34
(+238%)
Base:
(SPY PE: 20.6, Growth: 296.1%)
$111.85
(+140%)
Bear:
(PE: 17.5, Growth: 296.1%)
$95.07
(+104%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (56x PE), but valuation improves significantly next year (29x PE) as earnings recover.
Trailing PE: 56.37 | Current EPS (TTM): $0.82
Bull Case
$99.70
(+114%)
Analyst growth 96.1%, PE expands to 62.0
Base Case
$90.64
(+94%)
Market implied 96.1%, PE stable at 56.4
Bear Case
$31.43
(-33%)
Severe decline -20.0%, PE contracts to 47.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 29.0 to 45.0
Stabilization Target:
$72.36
(+55.2%)
PE Expansion Potential:
+55.2%
Share & Embed Analysis
Last updated: April 29, 2026 9:57 AM ET
Data refreshes hourly during market hours. Next update: 10:57 AM
Data refreshes hourly during market hours. Next update: 10:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CORT showing a specific setup today?
Insider Activity (6 Months)
1
Buys
16
Sells
Net
INSIDERS SELLING
Recent Transactions
William Guyer
SELL
20000 shares
2026-04-07
Joseph K Belanoff
SELL
26198 shares
2026-03-25
William Guyer
SELL
11767 shares
2026-03-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$449 | 52 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 60 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 57 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$32 | 67 BUY |
Advanced CORT Option Strategies
Professional options setups generated by AI based on today's CORT price and gamma walls.
